NuVasive, Inc. (NUVA) EPS Estimated At $0.56

January 22, 2018 - By Peter Erickson

 NuVasive, Inc. (NUVA) EPS Estimated At $0.56
Investors sentiment decreased to 0.95 in 2017 Q3. Its down 0.28, from 1.23 in 2017Q2. It fall, as 67 investors sold NuVasive, Inc. shares while 69 reduced holdings. 47 funds opened positions while 82 raised stakes. 53.88 million shares or 3.45% less from 55.81 million shares in 2017Q2 were reported.
Atlantic Lc holds 14,415 shares. Parametric Associate Ltd Liability owns 0% invested in NuVasive, Inc. (NASDAQ:NUVA) for 48,987 shares. First Trust Advsrs Lp holds 0% in NuVasive, Inc. (NASDAQ:NUVA) or 29,695 shares. Employees Retirement Association Of Colorado reported 0% stake. Gabelli Funds Ltd Liability Corp accumulated 371,500 shares. Ontario – Canada-based Royal Financial Bank Of Canada has invested 0.03% in NuVasive, Inc. (NASDAQ:NUVA). National Bank & Trust Of America Corporation De holds 0.01% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 880,126 shares. Spectrum Incorporated owns 0% invested in NuVasive, Inc. (NASDAQ:NUVA) for 16 shares. Liberty Mutual Grp Asset Mgmt holds 0.04% or 13,252 shares in its portfolio. Bancorp Of Nova Scotia holds 162,593 shares or 0.05% of its portfolio. Profit Investment Mgmt Limited Liability Corp invested in 1.71% or 35,336 shares. Moreover, Disciplined Growth Inc Mn has 0.08% invested in NuVasive, Inc. (NASDAQ:NUVA) for 66,007 shares. Manufacturers Life Ins Communication The reported 0.01% stake. Amalgamated Bancshares owns 6,975 shares for 0.01% of their portfolio. Stephens Invest Mngmt Grp Limited Liability invested in 684,079 shares or 0.88% of the stock.

Since August 17, 2017, it had 0 insider buys, and 1 sale for $256,621 activity.

Analysts expect NuVasive, Inc. (NASDAQ:NUVA) to report $0.56 EPS on February, 8.They anticipate $0.03 EPS change or 5.66 % from last quarter’s $0.53 EPS. NUVA’s profit would be $28.55 million giving it 23.33 P/E if the $0.56 EPS is correct. After having $0.52 EPS previously, NuVasive, Inc.’s analysts see 7.69 % EPS growth. The stock increased 0.35% or $0.18 during the last trading session, reaching $52.26. About 604,625 shares traded. NuVasive, Inc. (NASDAQ:NUVA) has risen 33.31% since January 22, 2017 and is uptrending. It has outperformed by 16.61% the S&P500.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

Among 22 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. Nuvasive Inc. had 64 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by RBC Capital Markets on Tuesday, July 18. The rating was maintained by RBC Capital Markets on Friday, September 8 with “Buy”. Wells Fargo downgraded the shares of NUVA in report on Wednesday, January 17 to “Market Perform” rating. As per Monday, October 16, the company rating was maintained by Cowen & Co. Needham downgraded NuVasive, Inc. (NASDAQ:NUVA) on Monday, August 28 to “Sell” rating. The firm has “Outperform” rating by Wells Fargo given on Wednesday, October 25. The firm has “Buy” rating given on Tuesday, October 3 by Jefferies. The rating was initiated by Aegis Capital with “Buy” on Wednesday, November 30. Canaccord Genuity maintained NuVasive, Inc. (NASDAQ:NUVA) rating on Friday, July 28. Canaccord Genuity has “Buy” rating and $8000 target. The firm has “Buy” rating by UBS given on Wednesday, August 16.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. The company has market cap of $2.66 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. It has a 44.9 P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

More recent NuVasive, Inc. (NASDAQ:NUVA) news were published by: which released: “NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF …” on January 04, 2018. Also published the news titled: “NuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And …” on January 08, 2018.‘s news article titled: “A Sluggish Spine Market Keeping The Pressure On NuVasive” with publication date: January 10, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: